Rivaroxaban review scheduled
Executive Summary
The Cardiovascular and Renal Drugs Advisory Committee will meet March 19 to review Johnson & Johnson/Bayer's novel factor Xa inhibitor Xarelto (rivaroxaban) for prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery, FDA announces. The NDA has a PDUFA date of May 29, 2009. The application is based on four Phase III studies - known as RECORD 1-4 - involving more than 12,500 patients (1"The Pink Sheet" DAILY, July 30, 2008). Bayer launched the oral anticoagulant in Europe in October 2008
You may also be interested in...
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.